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Abstract
Human African trypanosomiasis (HAT), or African sleeping sickness, is a fatal disease
found throughout sub-Saharan Africa. The disease is close to elimination in many areas,
although it was similarly close to elimination once before and subsequently reemerged,
despite seemingly low rates of transmission. Determining how these foci persisted and over-
came an apparent transmission paradox is key to finally eliminating HAT. By assessing clini-
cal, laboratory, and mathematical data, we propose that asymptomatic infections contribute
to transmission through the presence of an overlooked reservoir of skin-dwelling parasites.
Our assessment suggests that a combination of asymptomatic and parasitaemic cases is
sufficient to maintain transmission at foci without animal reservoirs, and we argue that the
current policy not to treat asymptomatic HAT should be reconsidered.
Introduction
Human African trypanosomiasis (HAT) is a deadly disease of sub-Saharan Africa caused by
two morphologically identical subspecies of the vector-borne parasite Trypanosoma brucei, T.
b. rhodesiense and T. b. gambiense. T. b. rhodesiense causes a more acute form of HAT and is
found predominantly in eastern Africa. T. b. gambiense is prevalent in western and central
Africa and leads to a more chronic disease. Although there has been a recent resurgence in
both forms of HAT, T. b. gambiense is by far the most common and represents over 97% of
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reported cases [1]. Both human infective forms are transmitted by tsetse flies (Glossina spp.)
and contribute to a cycle of poverty in some of the poorest regions of sub-Saharan Africa, pre-
dominantly in T. b. gambiense endemic areas. HAT is one of the diseases targeted by the
WHO 2020 and 2030 elimination goals and, as a result of concerted control measures, the
number of annual cases dropped from 22,800 reported (300,000 estimated) cases in 1995 to
less than 3,000 reported cases in 2015 and is now approaching elimination in many countries
[2]. The disease was similarly close to elimination during the 1960s when intensive control
efforts reduced the number of reported cases to just 5,000. Thereafter, political turmoil, cou-
pled with a decline in screening and control programmes, led to a rapid rise and reemergence
of several high-prevalence foci, with reported cases reaching a new peak by the end of the 20th
century [2]. Renewed HAT control and surveillance efforts through bilateral cooperation
between WHO, various nongovernment organisations (NGOs), and African administrations
over the last two decades have again presented an opportunity to finally eliminate this debili-
tating and deadly disease [2]. However, success depends on understanding the mechanisms
that led to the persistence and reemergence of HAT in low-transmission settings.
The transmission paradox
A key issue is the apparent transmission paradox that surrounds the disease as it approaches
elimination, particularly with regards T. b. gambiense. Although T. b. rhodesiense often pres-
ents with a high parasitaemia, there are relatively few parasites observed in a typical T. b. gam-
biense infection. Combined with the small volume of a tsetse blood meal (approximately 10 to
30 μL) that limits the opportunity to ingest a parasite, the difficulty in establishing an infection
in the tsetse and the low prevalence of infected vectors at many foci [3], it would seem T. b.
gambiense transmission should have ceased. These issues lead to the obvious questions: how
does T. b. gambiense HAT persist, and how did it return from apparent elimination? Several
hypotheses to explain the persistence and reemergence of T. b. gambiense HAT foci have been
proposed, including animal reservoirs, the use of suboptimal diagnostic methods, underre-
porting, and the possible involvement of infectious but persistently asymptomatic individuals
[4]. Although trypanosome-infected animals have been detected in many HAT foci, and it is
generally accepted that such reservoirs contribute to the maintenance and transmission of T.
b. rhodesiense, this is not universally the case for T. b. gambiense. The role that animal reser-
voirs may play in T. b. gambiense HAT foci persistence has recently been reviewed, suggesting
that they contribute to transmission maintenance in some areas [5]. However, there are T. b.
gambiense HAT foci that have few or no infected domestic animals despite intensive sampling,
indicating that the disease could be maintained by predominantly human infections (or an as
yet unidentified wild animal reservoir) [3]. Recently, evidence has also emerged to suggest that
aparasitaemic asymptomatic human infections may constitute an overlooked reservoir of dis-
ease that contributes to the maintenance of disease foci [6].
Resolving the paradox
Counter to the long-standing belief that HAT is always fatal in the absence of treatment, recent
studies suggest that some individuals infected with T. b. gambiense are able to tolerate the para-
site with few specific symptoms [7]. This has not yet been demonstrated in T. b. rhodesiense.
These asymptomatic individuals infected with T. b. gambiense are serologically positive but
microscopy negative when their blood is examined, even when assayed via the trypanolysis
(TL) test that eliminates false positives [8]. In some individuals, lymph node aspirate was also
examined and was similarly negative. Current diagnostic protocols for definitive diagnosis of
both T. b. rhodesiense and T. b. gambiense HAT rely on the visible identification of parasites in
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the blood or lymph node aspirate. As asymptomatic infected individuals in T. b. gambiense
areas do not present with disease symptoms and have undetectable parasitaemia, they are not
diagnosed via passive surveillance, and their potential impact on transmission is overlooked.
Even under active surveillance schemes, serologically positive but aparasitaemic and asymp-
tomatic individuals are not treated due to the toxicity of available drugs (pentamidine and
eflornithine), potentially meaning they continue to contribute to transmission.
This asymptomatic infection period can be extremely protracted, if not indefinite, with a
recent case persisting for 29 years before the patient developed symptoms [9]. The ability to
occasionally detect parasite genetic material using PCR from these individuals supports the
assertion that they harbour active infections, and they have consequently received increased
attention in recent years. For example, over a two-year follow-up in the Fore´cariah focus in
Guinea, approximately 13% of serologically positive individuals without visible parasites in an
initial screen developed clinical symptoms and parasitaemia [10], suggesting that these indi-
viduals were early-stage clinical cases or had been subsequently reinfected by a tsetse fly. Of
the remaining positive cases, 39% became serologically negative (indicating clearance of infec-
tion or an initial false positive serology result), whereas 48% remained seropositive for at least
two years [10], consistent with harbouring latent T. b. gambiense infections. As previously
mentioned, few infected animals have been identified in similar settings in Guinea, suggesting
that transmission is primarily human to human [3]. Although it may be possible that asymp-
tomatic animal reservoirs harbouring parasites exist, molecular and serological techniques
used to identify human asymptomatic cases would also have detected asymptomatic animals,
suggesting that there are few such infected animals in these T. b. gambiense foci. Although
transmission in this focus appears to be largely human to human, it is unclear what contribu-
tion asymptomatic human infections may make to transmission. To address this, we adapted a
previously published mathematical model [11] and parameterised it using data from the Fore´-
cariah focus [10] to simulate a polymorphic human population (Fig 1). This analysis suggests
that both asymptomatic and clinical cases are required to maintain HAT in the absence of ani-
mal reservoirs and indicates that long-term asymptomatic human infections may indeed rep-
resent an important but overlooked source of transmission. In order to detect both
symptomatic and asymptomatic infected individuals, active rather than passive surveillance is
required for HAT monitoring. As the number of symptomatic cases falls, the proportion of
infected individuals that harbour asymptomatic infections will consequently rise, representing
a new challenge to elimination.
The skin as a reservoir
There are several lines of evidence supporting the suggestion that asymptomatic individuals
harbour trypanosomes in their skin and thus form an anatomical reservoir for T. b. gambiense,
including xenodiagnosis assays showing that asymptomatic and symptomatic infected humans
and animals are able to infect tsetse flies [12,13]. These experiments provide independent
validation that tsetse flies can become infected despite feeding on hosts with undetectable
parasitaemia, indicating that the parasites are derived from an extravascular location. We
hypothesise that the skin is a likely source of these infective trypanosomes due to experimental
work in mice, indicating that animals with no visible parasitaemia have extravascular parasites
in their dermis and are infectious to the tsetse fly vector [6,14]. The presence of T. brucei para-
sites outside the vasculature of the host was recognised in the original characterisation of the
disease, although this understanding has been gradually eclipsed by descriptions of T. brucei as
largely a blood parasite. This is in part due to a reliance on the detection of blood parasites for
diagnosis.
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Recent developments have begun to refocus attention on the existence and significance of
extravascular skin-dwelling parasites. These include the description of a T. brucei adipose tis-
sue form (ATF) in mice, a distinct life-cycle stage of the parasite that exploits fatty acid oxida-
tion to survive in the lipid-rich environment of host adipose tissue [15]. The high density of
adipose tissue in the skin would make this a likely site for these forms, although there is not yet
any direct evidence of ATF parasites in the skin. Independent experiments have also shown
that trypanosomes recently inoculated into mouse skin by tsetse flies reside close to dermal
adipocytes and can be retransmitted [14]. Immunohistological analysis of archived human
skin punches has found trypanosomes in the skin of individuals not previously diagnosed with
HAT, consistent with the hypothesis that these are asymptomatic infections with transmissible
extravascular parasites [6]. The hypothesis that asymptomatic individuals harbour skin-dwell-
ing trypanosomes is currently being formally tested in an immunohistological survey of skin
biopsies from infected individuals in Guinea.
Given the mean unstressed intravascular volume of the blood (3.8 L) and the average vol-
ume of the skin (3.6 L), skin-dwelling parasites may represent a significant population of
Fig 1. Modelling of the relative contributions of asymptomatic and clinical cases to R0 in a polymorphic human
HAT focus without animal reservoirs. We estimated the contribution of asymptomatic and clinical infections to R0
(the basic reproductive number) under equilibrium prevalence by adapting a previously published trypanosomiasis
transmission model [11]. Consistent with empirical data showing no domestic or wildlife reservoir, we removed the
nonhuman-animal contribution to R0 and instead allowed for a polymorphic human population in which a fraction (f)
of the population develop clinical infections when infected (population I), with the remainder (1–f) developing
asymptomatic infections (population II). This leads to R0 ¼
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prevalence, II� is the number of clinical infections present at equilibrium, III� is the number of asymptomatic infections
at equilibrium, and N is the total human population size. We simulated this equation with epidemiologic and
demographic surveys from the Fore´cariah focus in Guinea. Specifically, there were 13 clinical infections and 16
suspected asymptomatic infections identified during the survey. Of the suspected asymptomatic individuals, one-third
tested negative on follow-up using the TL test and one-third developed symptoms [10]. Therefore, we set the number
of asymptomatic infections as III� = 16X (where X~Uniform(1/3,1)) and the number of clinical infections as II� = 29–
III�. The total population size was set as N = 10,837, based on 7,586 surveyed individuals and a survey completeness of
70%. These results suggest that transmission is not sustainable (R0 < 1) when nearly all infections are either clinical
(f> 0.98) or asymptomatic infections (f< 0.02). The shaded areas represent 95% predictive intervals when the number
of asymptomatic and clinical infections were sampled 1,000 times. HAT, human African trypanosomiasis; TL,
trypanolysis.
https://doi.org/10.1371/journal.pbio.3000105.g001
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dividing parasites in a chronic HAT infection that is similar in size to the population of blood
parasites. The strategy of residing in the skin may have evolved to maximise passage by telmo-
phagus (slash and suck) insects, like tsetse flies, that rupture the skin rather than feeding on
blood directly from active vessels. Indeed, other parasites that exist in the skin of the host, such
as Leishmania and Onchocerca, rely on telmophagus vectors for transmission.
Future perspectives
There is, therefore, clear evidence from both human and animal studies that skin invasion
occurs during T. brucei infection and likely represents an anatomical reservoir that could
resolve the transmission paradox of T. b. gambiense transmission and maintenance at foci
without animal reservoirs. The hypothesis that T. b. gambiense infection can lead to the asymp-
tomatic carriage of transmissible parasites has important implications for the WHO 2020 and
2030 HAT elimination goals [2]. Current policy does not advise the treatment of individuals
without confirmation of parasites in bodily fluids due to the toxic nature of currently available
drugs. However, identification and treatment of asymptomatic infections could improve the
effectiveness of disease control approaches and increase the likelihood of HAT elimination at
persistent foci. Such efforts could be bolstered by vector-control measures aimed at decreasing
human and tsetse contact, with prior studies demonstrating that such efforts [16] reduced T. b.
gambiense transmission [17]. Although it would not be advisable for asymptomatic individuals
to be treated with currently available drugs due to their toxicity, the development of less harm-
ful alternatives and improving the identification of asymptomatic individuals may remove this
barrier. For example, oral fexinidazole and acoziborole have both been shown to be almost as
effective as current treatments but with much less toxicity [18,19]. However, it is essential that
the capacities of these new drugs to treat skin-dwelling parasites are also ascertained, although
only in-hospital and under strictly controlled administration. If efficacy is demonstrated, we
argue that there should be a reassessment of the policy not to treat asymptomatic individuals,
in addition to concerted surveillance efforts to improve the diagnosis and identification of
such individuals. This would potentially remove an important reservoir for T. b. gambiense
HAT in many areas, reducing transmission and contributing to the elimination of this devast-
ing disease.
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